Connect with us

Industry

Target Healthcare to produce Bedrolite medical cannabis oil in UK

The Dutch government will continue to supply medicine to existing patients for a further three months.

Published

on

Target Healthcare to produce Bedrolite medical cannabis oil in UK
Target is said to have produced several batches of Bedrolite oil.

Estimated reading time: 4 minutes

Target Healthcare is set to manufacture Bedrolite medical cannabis oil in the UK, as the cut off for importing medicines from the Netherlands is extended again. 

Families of children using medical cannabis oils from the Dutch firm Bedrocan, have been informed that Target Healthcare will supply the high-CBD oil Bedrolite for patients in the UK.

In a letter, seen by Cannabis Health, the Department of Health and Social Care revealed that the Glasgow-based firm has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture cannabis-based products for medicinal use.

A number of patients with refractory epilepsy, two or whom have an NHS prescription, are currently using Bedrocan’s products in the UK and have seen their seizures significantly reduced and quality of life improved.

Until now these been dispensed by the Transvaal pharmacy in the Netherlands.

CBD: A banner advert for Always Pure Organics CBD business support

Target is said to have already produced several batches of Bedrolite oil after the Home Office amended its temporary licence, to ensure patients were not left without medication following supply issues last month.

It is now progressing its application for a full schedule one licence with the Home Office, which will allow it to produce Bedica and Bedrocan oil, which are also used by a number of children and contain higher levels of THC.

The letter also confirms that an agreement has been reached with the Dutch government to continue supplying medicine for existing patients for a further three months until 1 July 2022 to allow for “full domestic production” to be completed.

Families were given two weeks’ notice that their medication could no longer be dispensed following the end of the Brexit transition period on 31 December, 2020.

In response to calls from campaigners, the Dutch government agreed to continue supplying the life-saving products until 1 July, 2021 while a more permanent solution was reached. This waiver period has since been extended again until 1 January, 2022.

Target is currently able to supply “quality assured” Bedrolite oils produced during its validation process to “ensure continuity of supply” for patients.

However, a full schedule one licence is required before Target will be able to routinely produce medicines which can be supplied to patients.

Families have welcomed the news of a UK supply of Bedrolite, but raised concerns about how long it would be before Bedica and Bedrocan were also available.

Bedrolite is a high CBD oil, containing less than one per cent THC and 7.5 per cent CBD. 

Bedica and Bedrocan both contain higher levels of THC (Bedica 14 per cent THC and Bedrocan 22 per cent THC) and less than one per cent CBD.

In children with complex epilepsy, switching products can result in a worsening of seizures and may even be life-threatening.

Karen Gray’s son Murray, nine, who has a rare condition known as Doose syndrome, has been seizure free since taking both Bedrolite, and Bedica oils.

Karen told Cannabis Health: “The fact that we now have a UK source of Bedrolite is great news, however Murray still needs Bedica, and some of the other children are using Bedrocan as well.

“The agreement is until July but this will likely need to be extended again, as it’s taken over a year for Target to make Bedrolite, it’s going to take another year before they can make Bedica, and that’s if they are even planning to do that.”

A Department of Health and Social Care spokesperson said: “Domestic manufacture of Bedrocan oils is currently being established in the UK.

“DHSC continues to work closely with the Dutch Government, the Home Office and MHRA to ensure uninterrupted supply of Bedrocan oils.

“We continue to update interested parties on our progress, and will do so until domestic manufacture of Bedrocan oils is established.”

Cannabis Health has approached Target Healthcare for comment. 

Home » Industry » Target Healthcare to produce Bedrolite medical cannabis oil in UK

Industry

CBD by British Cannabis™ launches in Selfridges

The brands collection of 100 per cent cannabis supplements will be available in one of the UK’s most famous premium-retailers.

Published

on

CBD by British Cannabis™ launches in Selfridges
The range will be available at Selfridges Londo, in the Beauty Hall, as well as online.

British Cannabis™ has launched its collection of 100 per cent cannabis supplements and cosmetics in one of the UK’s most famous premium-retailers.

From today (Monday 4 July) the full range of CBD by British Cannabis™ products debuts in Selfridges London at the new Feel Good Bar, located in the Beauty Hall, as well as online.

Since launching seven years ago, British Cannabis™ (listed as CBD Health Foods Ltd) has experienced exceptional demand for its high quality and great tasting CBD products.

Today, the company is to launch their premium, flagship range in Selfridges.

The CBD by British Cannabis™ collection will be showcased in the Beauty Hall at Selfridges London, a place to discover products that spark innovative wellbeing practices and thought-provoking ideas and home to world-leading brands. 

CBD by British Cannabis™ products have won multiple awards in recent years, including the Highly Commended 2021, P3 MVP Award for 1000mg CBD Cannabis Oils, ICP magazine’s 2022 CBD Product of The Year, and Your Healthy Living magazine’s 2022 Silver Award for Best CBD Products (for CBD by British Cannabis™ Dermal Patches 500mg).

All of the food supplement products in the CBD by British Cannabis™ collection are included on the Food Standards Agency’s public list of products that are legal for sale on the UK market via the successful submission of British Cannabis’™ Novel Foods applications.

A recent update by the governments Food Standards Agency saw British Cannabis™ ranked as the UK’s largest CBD manufacturer by number of publicly listed CBD products manufactured. 

Read more industry news at Cannabis Wealth

More than just CBD – The British Cannabis™ Story

CBD by British Cannabis™ is not ‘just CBD’; these 100 per cent cannabis products contain hundreds of other beneficial cannabis compounds, terpenes, flavonoids, phenols and more.

All of these natural elements and yet still being compliant with regulations and legal for sale within the UK. Each product is rigorously tested for accuracy, purity, and THC-free status for consumer peace of mind. 

Every product contains the knowledge and expertise that has been amassed over the last seven years of British Cannabis™ existence, evidenced in the growing, extraction, research, development, and manufacturing that saw this British start-up grow to be the leading authority in consumer cannabis products within the UK.

British Cannabis™ CEO, Thomas Whettem, celebrated the news, commenting: This is yet another great milestone in the British Cannabis™ story. It is a testament to the levels of excellence we demand within our supply chain and products, that we are now stocked at an iconic, prestige retailer in Selfridges. 

“We set out to create ‘the champagne of CBD oils’, with more beneficial cannabis phytochemicals than any other CBD products compliant and legal for sale today. Our premium, THC-free products are both UK-born and UK-manufactured, thus debuting in Selfridges London seems very appropriate.”

British Cannabis™ launched a television campaign in March 2022 for its premium flagship range, CBD by British Cannabis™, as part of a half a million pound investment in awareness building and consumer recruitment 2022/23. 

Set in the style of a classic health and beauty advert, the creative aimed to break down barriers to legal cannabis-derived products, gaining broadcaster approval to make more industry-specific references than any campaign to date. 

Shown across dozens of premium channels on the SKY and Channel 5 networks, this marked the first time that the SKY network had opened its doors to CBD advertisers on their linear stations since 2019.

British Cannabis™ Managing Director, David Ralson, said: “As proud as we are of our tested, trusted, super-premium CBD supplements and cosmetics, we are equally proud to now be bringing them to the world-class shopping experience at Selfridges, as part of our distribution expansion plans.

“For over a century, Selfridges have brought premium health and beauty products to the forefront in exciting ways – and especially in their new Feel Good Bar. As one of the UK’s original British-made CBD ranges, with a heritage in this young industry of nearly seven years, the match of Selfridges and CBD by British Cannabis™ seems a perfect fit.

“I hope that Selfridges shoppers grow to love and trust our CBD range as much as our existing loyal customer base, who over the years have given us over 1,500 5-star reviews on Trustpilot.”

BRITISH CANNABIS™ can be reached on +44 (0) 203 965 2420 or via email at [email protected]

Find us on LinkedIn – Search ‘BRITISH CANNABIS’ or search ‘@BritishCanna’ for Facebook and Twitter.

Home » Industry » Target Healthcare to produce Bedrolite medical cannabis oil in UK

Continue Reading

Industry

New fully digital cannabis dispensary launches in UK

It aims to streamline the process through which  cannabis patients can access their medicine.

Published

on

New fully digital cannabis dispensary launches in UK

A new fully digital medical cannabis pharmacy aims to improve the dispensing experience for UK patients.

A new digital dispensing solution has launched in the UK, with the aim of streamlining the process through which cannabis patients can access their medicine.

Through the new system, patients are able to schedule delivery to their home or office, with a 120-minute delivery service in London and Birmingham and next-day delivery across the UK.

Akanda subsidiary, CanMart, has partnered with digital pharmacy infrastructure Phlo Connect and Cellen Life Sciences to bring the project to life.

The process will be increasingly seamless for patients in the near future as Phlo Connect, Cellen and CanMart build additional digital interconnections, Akanda said.

Osteoarthritis: A banner advert for the medical cannabis clinicsTej Virk, CEO of Akanda, said: “Akanda is committed to expanding access to high-quality products for anyone in need, and that is qualified in the United Kingdom, a growing market for medical cannabis.

“Phlo Connect and Cellen are the ideal partners to make this happen, combining the UK’s first fully digital pharmacy with a digital dispensing model that is easy to use, secure, and real-time.

“In the nascent UK medical cannabis market, patients currently suffer from excess friction as the prescription process, and last-mile delivery is disjointed.

“We firmly believe that our solution is the best way to satisfy patients and get our 1P and 3P-supplied medical cannabis in their hands quickly and conveniently, which will greatly improve the patient experience.”

New fully digital cannabis dispensary launches in UK

The partnership with Phlo Connect builds on CanMart’s existing partnership with Cellen, a health tech company that provides treatment to chronic pain patients through Leva Clinic, as well as through partners including the NHS, and Boots UK.

The Leva Clinic, which is licensed and regulated by the Care Quality Commission, is one of the first fully digital pain clinics in the UK.

Cellen is also a medical cannabis supplier to Project Twenty21, the large-scale medical cannabis observational study monitored by Drug Science that aims to improve access to medical cannabis.

Adam Hunter, CCO of Phlo Connect commented: “We believe partnering with CanMart and Cellen will be a game-changer for medicinal cannabis patients here in the UK.

“By integrating with both CanMart and Cellen via our API-driven pharmacy platform, we believe that this partnership is the first truly end-to-end digital experience for medicinal cannabis patients in the UK.”

He added: “Our patients require access to new high-quality products without the friction and hassle of traditional dispensing services. This partnership is another example of our continuing efforts to build on our national, established relationships with the wider pharmaceutical community in innovative ways.

“We believe that CanMart’s access to high quality products as well as Phlo Connect’s extensive capabilities in dispensing will go a long way to helping our service to our patients.”

Home » Industry » Target Healthcare to produce Bedrolite medical cannabis oil in UK

Continue Reading

Industry

CiiTECH celebrates five years with five days of CBD offers

CiiTECH’s five-year birthday is a pivotal moment, the company said.

Published

on

ciitech

Cannabis healthcare company CiiTECH celebrates its fifth birthday and reflects on a turbulent half-decade for the CBD industry.

CiiTECH’s five-year birthday is a pivotal moment, the company said. After what has been one of the most turbulent times for the industry, the firm has achieved six months of stability. With new crypto projects on the horizon and new markets on the cards, the company is gearing up for a period of growth.

CBD is a tough industry to be in right now but that has never stopped CiiTECH CEO and founder, Clifton Flack, from driving the business through regulatory issues and the challenges of an increasingly saturated market.

“When we started the business in 2017 the market was approaching the peak of interest and excitement. Since then, alongside the hundreds of brands that have been born to compete with us, we’ve also faced monumental regulatory pressures and flip-flopping,” Flack said.

“We’re still here though, independent and with a bright future ahead as the coming year ahead brings settled regulations.”

After a stormy start to the year, the FSA delivered on their promise to roll out a framework by which products can be set on a supervised pathway to novel food authorisation. The market is now more difficult than ever to penetrate for new and emerging brands, however it gives established UK CBD companies like CiiTECH an advantage over international companies attempting to penetrate the UK market.

“In parallel, the industry and our peers have had a two year pandemic, Brexit supply chain disruptions and now a cost of living crisis set to put all previous volatilities to shame,” Flack added.

“Now more than ever, cannabis healthcare companies need to take our time, avoid the panic and focus on delivering quality products behind trusted brands that are built for the long term.”

Recently, CiiTECH investigated a stock market listing on the London Stock Exchange but the IPO did not come to fruition.

“As the CEO, I had to make an impossible decision,” Flack said.

“Amongst other things, the timing was just not right. Consumer sentiment and demands are volatile and we found the essence of our company getting lost in bureaucracy at a time when it should have been front of mind.

Yesterday, CiiTECH launched five promotions over five days to celebrate the anniversary of the company.

“As a revenue-driven business, CiiTECH would not be in the position it is today without its army of loyal Provacan customers, so we’re giving back to them the best way we know-how.

“With five days’ worth of promos and freebies to mark five years of success. Our Friday promo emails have become somewhat legendary among our customers but we have never done anything like this before.”

Continue Reading

Trending